Katharine Anne Mitchell, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 25101 The Old Rd, Newhall, CA 91381 Phone: 661-249-9940 Fax: 661-418-5676 |
Km Speech And Language Pathology, Inc. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 23121 Coltrane Ave, Newhall, CA 91321 Phone: 818-624-4001 |
Julie C Speak, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 23504 Lyons Ave Ste 103b, Newhall, CA 91321 Phone: 661-253-0245 Fax: 661-253-0310 |
Jennifer Alvarez, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 23504 Lyons Ave Ste 103b, Newhall, CA 91321 Phone: 661-253-0245 |
Ms. Perveen M Katrack, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 23504 Lyons Ave, Suite 103 B, Newhall, CA 91321 Phone: 661-253-0245 Fax: 661-253-0310 |
News Archive
Researchers at Jefferson's Kimmel Cancer Center in Philadelphia have shown that they can effectively kill prostate cancer cells in both the laboratory and in experimental animal models by blocking a signaling protein that is key to the cancer's growth.
Reporting for Kaiser Health News, in collaboration with The Washington Post, Lawrence Lindner writes: "The Obama administration's bid to slash funding for training pediatricians at children's hospitals is provoking intense protests from medical educators and lawmakers on both sides of the aisle".
Pneumonia is the leading cause of death of young children around the world, and a study from an international group of researchers now finds that the risk of poor outcomes - including persistent pneumonia, secondary infections, organ failure or death - in children who contract pneumonia is four times higher in those who also have anemia and live at high altitudes (over 2,000 meters or about 6,500 feet).
Medical implants like stents, catheters and tubing introduce risk for blood clotting and infection - a perpetual problem for many patients.
Metabolic Solutions Development Company, a drug discovery and development company exploiting novel molecular targets to treat metabolic diseases, announced today that it has launched a Phase 2a trial for MSDC-0602, the company's second drug candidate for the treatment of type 2 diabetes.
› Verified 2 days ago